Biomarker-driven approaches, such as ERCC1 expression in metastatic melanoma (101) and an 8-gene signature in sarcomas CDKN2A, PIK3R1, SLFN11, ATM, APEX2, BLM, XRCC2, MAD2L2 that may help predict better outcomes (102, 103), offer potential for tailoring therapies. This evidence concerns the gene APEX2 and metastatic melanoma.